Mir-224/mir-141 ratio as a novel diagnostic biomarker in renal cell carcinoma

Xuanyu Chen, Ning Lou, Anming Ruan, Bin Qiu, Yun Yan, Xuegang Wang, Quansheng Du, Hailong Ruan, Weiwei Han, Haibin Wei, Hongmei Yang, Xiaoping Zhang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Biomarkers to guide the clinical treatment of patients with renal cell carcinoma (RCC) are not yet routinely available. MicroRNAs (miRNAs) have been demonstrated to serve as biomarkers for a number of types of cancer. Based on a previous study by this group, we hypothesize that several highly differentially expressed miRNAs may serve as tissue and plasma biomarkers in patients with RCC. The expression levels of miR-210, miR-224 and miR-141 were analyzed in tissue samples from the same cohort of 78 patients with RCC, in paired pre- and post-operative plasma samples from 66 patients with clear cell RCC (ccRCC) and in 67 healthy controls by reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic (ROC) was used to evaluate the diagnostic accuracy associated with the expression of miR-210, miR-224 and miR-141. ROC curves revealed that the diagnostic accuracy (area under the curve) of tissue miR-210, miR-224, the ratio of miR-210/miR-141 (miR210/141), miR-224/miR-141 (miR224/141) and miR-210x miR-224/miR-141 (miR210x224/141) in ccRCC was 0.8329, 0.8511, 0.9412, 0.9898 and 0.9771, respectively. Notably, miR224/141 demonstrated the highest accuracy among these miRNAs for discriminating ccRCC tissues from normal tissues, with a sensitivity of 97.06% and a specificity of 98.53%. The expression levels of plasma miR-210 and miR-224 were significantly increased in patients compared with healthy control patients, and were reduced postoperatively (P<0.05). The diagnostic accuracy of plasma miR-210 and miR-224 were 0.6775 (89.55% sensitivity and 48.48% specificity) and 0.6056 (88.06% sensitivity and 40.91% specificity), respectively. The present study indicated that the tissue miR-224/miR-141 ratio is a potentially powerful tool for detecting ccRCC. However, plasma miR-210 and miR-224 may not be associated with diagnosis of ccRCC.

Original languageEnglish (US)
Pages (from-to)1666-1674
Number of pages9
JournalOncology Letters
Volume16
Issue number2
DOIs
StatePublished - Aug 2018

Fingerprint

Renal Cell Carcinoma
Biomarkers
MicroRNAs
ROC Curve
Sensitivity and Specificity
Reverse Transcription
Area Under Curve
Polymerase Chain Reaction
Clear-cell metastatic renal cell carcinoma
Neoplasms

Keywords

  • Biomarker
  • Diagnosis
  • MiR-210
  • MiR-224
  • Plasma
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chen, X., Lou, N., Ruan, A., Qiu, B., Yan, Y., Wang, X., ... Zhang, X. (2018). Mir-224/mir-141 ratio as a novel diagnostic biomarker in renal cell carcinoma. Oncology Letters, 16(2), 1666-1674. https://doi.org/10.3892/ol.2018.8874

Mir-224/mir-141 ratio as a novel diagnostic biomarker in renal cell carcinoma. / Chen, Xuanyu; Lou, Ning; Ruan, Anming; Qiu, Bin; Yan, Yun; Wang, Xuegang; Du, Quansheng; Ruan, Hailong; Han, Weiwei; Wei, Haibin; Yang, Hongmei; Zhang, Xiaoping.

In: Oncology Letters, Vol. 16, No. 2, 08.2018, p. 1666-1674.

Research output: Contribution to journalArticle

Chen, X, Lou, N, Ruan, A, Qiu, B, Yan, Y, Wang, X, Du, Q, Ruan, H, Han, W, Wei, H, Yang, H & Zhang, X 2018, 'Mir-224/mir-141 ratio as a novel diagnostic biomarker in renal cell carcinoma', Oncology Letters, vol. 16, no. 2, pp. 1666-1674. https://doi.org/10.3892/ol.2018.8874
Chen, Xuanyu ; Lou, Ning ; Ruan, Anming ; Qiu, Bin ; Yan, Yun ; Wang, Xuegang ; Du, Quansheng ; Ruan, Hailong ; Han, Weiwei ; Wei, Haibin ; Yang, Hongmei ; Zhang, Xiaoping. / Mir-224/mir-141 ratio as a novel diagnostic biomarker in renal cell carcinoma. In: Oncology Letters. 2018 ; Vol. 16, No. 2. pp. 1666-1674.
@article{39ababdd993c49969035df8cb4da107d,
title = "Mir-224/mir-141 ratio as a novel diagnostic biomarker in renal cell carcinoma",
abstract = "Biomarkers to guide the clinical treatment of patients with renal cell carcinoma (RCC) are not yet routinely available. MicroRNAs (miRNAs) have been demonstrated to serve as biomarkers for a number of types of cancer. Based on a previous study by this group, we hypothesize that several highly differentially expressed miRNAs may serve as tissue and plasma biomarkers in patients with RCC. The expression levels of miR-210, miR-224 and miR-141 were analyzed in tissue samples from the same cohort of 78 patients with RCC, in paired pre- and post-operative plasma samples from 66 patients with clear cell RCC (ccRCC) and in 67 healthy controls by reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic (ROC) was used to evaluate the diagnostic accuracy associated with the expression of miR-210, miR-224 and miR-141. ROC curves revealed that the diagnostic accuracy (area under the curve) of tissue miR-210, miR-224, the ratio of miR-210/miR-141 (miR210/141), miR-224/miR-141 (miR224/141) and miR-210x miR-224/miR-141 (miR210x224/141) in ccRCC was 0.8329, 0.8511, 0.9412, 0.9898 and 0.9771, respectively. Notably, miR224/141 demonstrated the highest accuracy among these miRNAs for discriminating ccRCC tissues from normal tissues, with a sensitivity of 97.06{\%} and a specificity of 98.53{\%}. The expression levels of plasma miR-210 and miR-224 were significantly increased in patients compared with healthy control patients, and were reduced postoperatively (P<0.05). The diagnostic accuracy of plasma miR-210 and miR-224 were 0.6775 (89.55{\%} sensitivity and 48.48{\%} specificity) and 0.6056 (88.06{\%} sensitivity and 40.91{\%} specificity), respectively. The present study indicated that the tissue miR-224/miR-141 ratio is a potentially powerful tool for detecting ccRCC. However, plasma miR-210 and miR-224 may not be associated with diagnosis of ccRCC.",
keywords = "Biomarker, Diagnosis, MiR-210, MiR-224, Plasma, Renal cell carcinoma",
author = "Xuanyu Chen and Ning Lou and Anming Ruan and Bin Qiu and Yun Yan and Xuegang Wang and Quansheng Du and Hailong Ruan and Weiwei Han and Haibin Wei and Hongmei Yang and Xiaoping Zhang",
year = "2018",
month = "8",
doi = "10.3892/ol.2018.8874",
language = "English (US)",
volume = "16",
pages = "1666--1674",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Mir-224/mir-141 ratio as a novel diagnostic biomarker in renal cell carcinoma

AU - Chen, Xuanyu

AU - Lou, Ning

AU - Ruan, Anming

AU - Qiu, Bin

AU - Yan, Yun

AU - Wang, Xuegang

AU - Du, Quansheng

AU - Ruan, Hailong

AU - Han, Weiwei

AU - Wei, Haibin

AU - Yang, Hongmei

AU - Zhang, Xiaoping

PY - 2018/8

Y1 - 2018/8

N2 - Biomarkers to guide the clinical treatment of patients with renal cell carcinoma (RCC) are not yet routinely available. MicroRNAs (miRNAs) have been demonstrated to serve as biomarkers for a number of types of cancer. Based on a previous study by this group, we hypothesize that several highly differentially expressed miRNAs may serve as tissue and plasma biomarkers in patients with RCC. The expression levels of miR-210, miR-224 and miR-141 were analyzed in tissue samples from the same cohort of 78 patients with RCC, in paired pre- and post-operative plasma samples from 66 patients with clear cell RCC (ccRCC) and in 67 healthy controls by reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic (ROC) was used to evaluate the diagnostic accuracy associated with the expression of miR-210, miR-224 and miR-141. ROC curves revealed that the diagnostic accuracy (area under the curve) of tissue miR-210, miR-224, the ratio of miR-210/miR-141 (miR210/141), miR-224/miR-141 (miR224/141) and miR-210x miR-224/miR-141 (miR210x224/141) in ccRCC was 0.8329, 0.8511, 0.9412, 0.9898 and 0.9771, respectively. Notably, miR224/141 demonstrated the highest accuracy among these miRNAs for discriminating ccRCC tissues from normal tissues, with a sensitivity of 97.06% and a specificity of 98.53%. The expression levels of plasma miR-210 and miR-224 were significantly increased in patients compared with healthy control patients, and were reduced postoperatively (P<0.05). The diagnostic accuracy of plasma miR-210 and miR-224 were 0.6775 (89.55% sensitivity and 48.48% specificity) and 0.6056 (88.06% sensitivity and 40.91% specificity), respectively. The present study indicated that the tissue miR-224/miR-141 ratio is a potentially powerful tool for detecting ccRCC. However, plasma miR-210 and miR-224 may not be associated with diagnosis of ccRCC.

AB - Biomarkers to guide the clinical treatment of patients with renal cell carcinoma (RCC) are not yet routinely available. MicroRNAs (miRNAs) have been demonstrated to serve as biomarkers for a number of types of cancer. Based on a previous study by this group, we hypothesize that several highly differentially expressed miRNAs may serve as tissue and plasma biomarkers in patients with RCC. The expression levels of miR-210, miR-224 and miR-141 were analyzed in tissue samples from the same cohort of 78 patients with RCC, in paired pre- and post-operative plasma samples from 66 patients with clear cell RCC (ccRCC) and in 67 healthy controls by reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic (ROC) was used to evaluate the diagnostic accuracy associated with the expression of miR-210, miR-224 and miR-141. ROC curves revealed that the diagnostic accuracy (area under the curve) of tissue miR-210, miR-224, the ratio of miR-210/miR-141 (miR210/141), miR-224/miR-141 (miR224/141) and miR-210x miR-224/miR-141 (miR210x224/141) in ccRCC was 0.8329, 0.8511, 0.9412, 0.9898 and 0.9771, respectively. Notably, miR224/141 demonstrated the highest accuracy among these miRNAs for discriminating ccRCC tissues from normal tissues, with a sensitivity of 97.06% and a specificity of 98.53%. The expression levels of plasma miR-210 and miR-224 were significantly increased in patients compared with healthy control patients, and were reduced postoperatively (P<0.05). The diagnostic accuracy of plasma miR-210 and miR-224 were 0.6775 (89.55% sensitivity and 48.48% specificity) and 0.6056 (88.06% sensitivity and 40.91% specificity), respectively. The present study indicated that the tissue miR-224/miR-141 ratio is a potentially powerful tool for detecting ccRCC. However, plasma miR-210 and miR-224 may not be associated with diagnosis of ccRCC.

KW - Biomarker

KW - Diagnosis

KW - MiR-210

KW - MiR-224

KW - Plasma

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85049440490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049440490&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.8874

DO - 10.3892/ol.2018.8874

M3 - Article

AN - SCOPUS:85049440490

VL - 16

SP - 1666

EP - 1674

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -